Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (361-370 of 738) with videos related to

Pageof 74
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.
Gynecologic Oncology|March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized studyKrishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
The Journal of Clinical Psychiatry|July 3, 2024
Controlled Study of Metabolic Syndrome Among Offspring of Parents With Bipolar DisorderNidhi P Kulkarni, Mikaela K Dimick, Kody G Kennedy, et al.
Gynecologic Oncology|July 10, 2020
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group studyWarner K Huh, William E Brady, Paula M Fracasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II StudyDavid M O'Malley, Maryna Neffa, Bradley J Monk, et al.
Cancer Medicine|May 7, 2021
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancerRobin L Jones, Thomas J Herzog, Shreyaskumar R Patel, et al.
Future Oncology (London, England)|August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancerDavid M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.
Obstetrics and Gynecology|January 6, 2022
Symptoms of Women With High-Risk Early-Stage Ovarian CancerJohn K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
The Lancet. Oncology|February 2, 2015
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)Richard T Penson, Helen Q Huang, Lari B Wenzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Pageof 74

Showing results (361-370 of 738) with videos related to

Sort By:
Pageof 74
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.
Gynecologic Oncology|March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized studyKrishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
The Journal of Clinical Psychiatry|July 3, 2024
Controlled Study of Metabolic Syndrome Among Offspring of Parents With Bipolar DisorderNidhi P Kulkarni, Mikaela K Dimick, Kody G Kennedy, et al.
Gynecologic Oncology|July 10, 2020
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group studyWarner K Huh, William E Brady, Paula M Fracasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II StudyDavid M O'Malley, Maryna Neffa, Bradley J Monk, et al.
Cancer Medicine|May 7, 2021
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancerRobin L Jones, Thomas J Herzog, Shreyaskumar R Patel, et al.
Future Oncology (London, England)|August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancerDavid M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.
Obstetrics and Gynecology|January 6, 2022
Symptoms of Women With High-Risk Early-Stage Ovarian CancerJohn K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
The Lancet. Oncology|February 2, 2015
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)Richard T Penson, Helen Q Huang, Lari B Wenzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Pageof 74